Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone.

Iskenderian A, Liu N, Deng Q, Huang Y, Shen C, Palmieri K, Crooker R, Lundberg D, Kastrapeli N, Pescatore B, Romashko A, Dumas J, Comeau R, Norton A, Pan J, Rong H, Derakhchan K, Ehmann DE.

Skelet Muscle. 2018 Oct 27;8(1):34. doi: 10.1186/s13395-018-0180-z.

2.

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.

Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, Lahiri S, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Velez-Vega C, Olivier NB, McLaughlin R, Gao N, Thresher J, Palmer T, Andrews B, Giacobbe RA, Newman JV, Ehmann DE, de Jonge B, O'Donnell J, Mueller JP, Tommasi RA, Miller AA.

Nat Microbiol. 2017 Jun 30;2:17104. doi: 10.1038/nmicrobiol.2017.104.

PMID:
28665414
3.

Untargeted Metabolomics To Ascertain Antibiotic Modes of Action.

Vincent IM, Ehmann DE, Mills SD, Perros M, Barrett MP.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2281-91. doi: 10.1128/AAC.02109-15. Print 2016 Apr.

4.

Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy.

Kim A, Kutschke A, Ehmann DE, Patey SA, Crandon JL, Gorseth E, Miller AA, McLaughlin RE, Blinn CM, Chen A, Nayar AS, Dangel B, Tsai AS, Rooney MT, Murphy-Benenato KE, Eakin AE, Nicolau DP.

Antimicrob Agents Chemother. 2015 Dec;59(12):7743-52. doi: 10.1128/AAC.00831-15. Epub 2015 Oct 5.

5.

Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.

Kern G, Palmer T, Ehmann DE, Shapiro AB, Andrews B, Basarab GS, Doig P, Fan J, Gao N, Mills SD, Mueller J, Sriram S, Thresher J, Walkup GK.

J Biol Chem. 2015 Aug 21;290(34):20984-94. doi: 10.1074/jbc.M115.663534. Epub 2015 Jul 6.

6.

Translating slow-binding inhibition kinetics into cellular and in vivo effects.

Walkup GK, You Z, Ross PL, Allen EK, Daryaee F, Hale MR, O'Donnell J, Ehmann DE, Schuck VJ, Buurman ET, Choy AL, Hajec L, Murphy-Benenato K, Marone V, Patey SA, Grosser LA, Johnstone M, Walker SG, Tonge PJ, Fisher SL.

Nat Chem Biol. 2015 Jun;11(6):416-23. doi: 10.1038/nchembio.1796. Epub 2015 Apr 20.

7.

Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model.

Murphy-Benenato KE, Bhagunde PR, Chen A, Davis HE, Durand-Réville TF, Ehmann DE, Galullo V, Harris JJ, Hatoum-Mokdad H, Jahić H, Kim A, Manjunatha MR, Manyak EL, Mueller J, Patey S, Quiroga O, Rooney M, Sha L, Shapiro AB, Sylvester M, Tan B, Tsai AS, Uria-Nickelsen M, Wu Y, Zambrowski M, Zhao SX.

J Med Chem. 2015 Mar 12;58(5):2195-205. doi: 10.1021/jm501506f. Epub 2015 Mar 3.

PMID:
25658376
8.

Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.

Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA.

Antimicrob Agents Chemother. 2015 Mar;59(3):1680-9. doi: 10.1128/AAC.04808-14. Epub 2015 Jan 5.

9.

Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48.

Lahiri SD, Mangani S, Jahić H, Benvenuti M, Durand-Reville TF, De Luca F, Ehmann DE, Rossolini GM, Alm RA, Docquier JD.

ACS Chem Biol. 2015 Feb 20;10(2):591-600. doi: 10.1021/cb500703p. Epub 2014 Dec 4.

PMID:
25406838
10.

Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor.

Nayar AS, Dougherty TJ, Reck F, Thresher J, Gao N, Shapiro AB, Ehmann DE.

Antimicrob Agents Chemother. 2015 Jan;59(1):331-7. doi: 10.1128/AAC.04077-14. Epub 2014 Oct 27.

11.

Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase.

Ehmann DE, Lahiri SD.

Curr Opin Pharmacol. 2014 Oct;18:76-83. doi: 10.1016/j.coph.2014.09.007. Epub 2014 Sep 29. Review.

12.

Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.

Reck F, Ehmann DE, Dougherty TJ, Newman JV, Hopkins S, Stone G, Agrawal N, Ciaccio P, McNulty J, Barthlow H, O'Donnell J, Goteti K, Breen J, Comita-Prevoir J, Cornebise M, Cronin M, Eyermann CJ, Geng B, Carr GR, Pandarinathan L, Tang X, Cottone A, Zhao L, Bezdenejnih-Snyder N.

Bioorg Med Chem. 2014 Oct 1;22(19):5392-409. doi: 10.1016/j.bmc.2014.07.040. Epub 2014 Aug 4.

PMID:
25155913
13.

NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.

Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE.

Antimicrob Agents Chemother. 2014 May;58(5):2657-64. doi: 10.1128/AAC.02778-13. Epub 2014 Feb 24. Erratum in: Antimicrob Agents Chemother. 2014 Jul;58(7):4250.

14.

Kinetics of avibactam inhibition against Class A, C, and D β-lactamases.

Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Réville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL.

J Biol Chem. 2013 Sep 27;288(39):27960-71. doi: 10.1074/jbc.M113.485979. Epub 2013 Aug 2.

15.

Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.

Reck F, Alm RA, Brassil P, Newman JV, Ciaccio P, McNulty J, Barthlow H, Goteti K, Breen J, Comita-Prevoir J, Cronin M, Ehmann DE, Geng B, Godfrey AA, Fisher SL.

J Med Chem. 2012 Aug 9;55(15):6916-33. doi: 10.1021/jm300690s. Epub 2012 Jul 20.

PMID:
22779424
16.

Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Ehmann DE, Jahić H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL.

Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11663-8. doi: 10.1073/pnas.1205073109. Epub 2012 Jul 2.

17.

The kinetic mechanism of S. pneumoniae DNA ligase and inhibition by adenosine-based antibacterial compounds.

Jahić H, Liu CF, Thresher J, Livchak S, Wang H, Ehmann DE.

Biochem Pharmacol. 2012 Sep 1;84(5):654-60. doi: 10.1016/j.bcp.2012.06.017. Epub 2012 Jun 26.

PMID:
22743594
18.

Biochemical characterization of an inhibitor of Escherichia coli UDP-N-acetylmuramyl-l-alanine ligase.

Ehmann DE, Demeritt JE, Hull KG, Fisher SL.

Biochim Biophys Acta. 2004 May 6;1698(2):167-74.

PMID:
15134649
19.

Chain termination steps in nonribosomal peptide synthetase assembly lines: directed acyl-S-enzyme breakdown in antibiotic and siderophore biosynthesis.

Keating TA, Ehmann DE, Kohli RM, Marshall CG, Trauger JW, Walsh CT.

Chembiochem. 2001 Feb 2;2(2):99-107. No abstract available.

PMID:
11828432
20.

Aminoacyl-SNACs as small-molecule substrates for the condensation domains of nonribosomal peptide synthetases.

Ehmann DE, Trauger JW, Stachelhaus T, Walsh CT.

Chem Biol. 2000 Oct;7(10):765-72.

21.
22.

Supplemental Content

Loading ...
Support Center